Diakonos Oncology secures funds for Phase II trial of dendritic cell vaccine
Diakonos Oncology secures $11.4m in seed financing to advance its dendritic cell vaccine candidate, DOC1021, into a Phase II clinical trial for glioblastoma treatment.
Highlighted Terms
Related News
Diakonos Oncology secures funds for Phase II trial of dendritic cell vaccine
Diakonos Oncology secures $11.4m in seed financing to advance its dendritic cell vaccine candidate, DOC1021, into a Phase II clinical trial for glioblastoma treatment.